Navigation Links
Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
Date:4/11/2008

TUSTIN, Calif., April 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapies for the treatment of cancer and hepatitis C virus infection (HCV), today announced that the following preclinical abstracts will be the subject of oral and poster presentations at the 2008 Annual Meeting of the American Association for Cancer Research (AACR), being held April 12-16, 2008 in San Diego:

-- "Targeting mutant p53 protein and tumor vasculature: An effective

combination therapy for advanced breast tumors" (Abstract #2341, New

Targets 1: Mechanisms Session) - Poster session scheduled for Monday,

April 14, 2008 from 8:00 am to 12:00 pm.

-- "An immunocytokine that binds to phosphatidylserine generates an

effective cell-based tumor vaccine in mice" (Abstract #2841, Tumor

Vaccines Session) - Poster session scheduled for Monday, April 14,

2008 from 1:00 pm to 5:00 pm.

-- "Combination of a monoclonal anti-phosphatidylserine antibody with

docetaxel strongly inhibits the growth and metastasis of

hormone-refractory prostate cancers in mice" (Abstract #2551, New

Approaches to Biological Therapy Session) - Oral presentation

scheduled for Monday, April 14, 2008 at 2:10 pm.

-- "Antibody targeting of phosphatidylserine produces a cytokine

microenvironment that enhances innate anti-tumor immune responses"

(Abstract #4079, Immunoconjugates, Peptides, and Protein Therapeutics

Session) - Poster session scheduled for Tuesday, April 15, 2008 from

8:00 am to 12:00 pm.

Abstracts and information abou
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
2. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
3. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
4. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
5. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
8. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
9. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... Edison Investment Research, ... the initiation of full coverage of BioAlliance ... and marketing products for orphan oncology and ... (Logo: http://photos.prnewswire.com/prnh/20130417/608168) Edison has today ... merits of BioAlliance Pharma, focusing in particular ...
(Date:6/18/2013)... DALLAS , June 18, 2013 ... Segment (Sequencing Platforms, Knowledge Management Tools & Data Analysis Services) ... analyzes and studies the Major Market Drivers, Restraints, and Opportunities ... , Asia-Pacific and Rest of ... Data Tables 22 Figures ...
(Date:6/18/2013)... -- Techne Corporation (NASDAQ: TECH ) (Techne) ... 100% ownership of Bionostics Holdings Limited and its ... global leader in the development, manufacture and distribution ... of in vitro diagnostic (IVD) devices ... and blood gas testing.  Biosnostics has strategic supply ...
(Date:6/18/2013)... DUBLIN , June 18, 2013 /PRNewswire/ ... http://www.researchandmarkets.com/research/5g3rx5/dna_sequencing ) has announced the addition of ... Markets and Companies " to their offering. ... This report briefly reviews basics of human ... their applications. Current large and small sequencers ...
Breaking Biology Technology:Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 2Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 3Bioinformatics Market Worth $7.5 Billion by 2017 2Bioinformatics Market Worth $7.5 Billion by 2017 3Techne Corporation Announces Acquisition Agreement 2Techne Corporation Announces Acquisition Agreement 3Techne Corporation Announces Acquisition Agreement 4Techne Corporation Announces Acquisition Agreement 5DNA Sequencing: Technologies, Markets and Companies - 2013 Report 2
... Reportlinker.com announces that a new market research report ... Immunogenicity to Biologics http://www.reportlinker.com/p0324747/Immunogenicity-to-Biologics.html ... body,s response to therapeutic proteins, is vitally important ... Failure to predict and monitor levels of immunogenicity ...
... Nov. 3, 2010 Sangamo BioSciences, Inc. ... has been awarded a total of $978,000 in grants ... Discovery Project Program. Under the recently ... section 48D of the Internal Revenue Code, cash grants ...
... Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that ... 180 days to regain compliance with NASDAQ,s $1.00 minimum bid ... 3, 2010, CTI was notified by NASDAQ that CTI did ... listing and was provided until November 1, 2010 to achieve ...
Cached Biology Technology:Reportlinker Adds Immunogenicity to Biologics 2Reportlinker Adds Immunogenicity to Biologics 3Reportlinker Adds Immunogenicity to Biologics 4Reportlinker Adds Immunogenicity to Biologics 5Reportlinker Adds Immunogenicity to Biologics 6Reportlinker Adds Immunogenicity to Biologics 7Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs 2Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs 3NASDAQ Grants Cell Therapeutics 180-Day Extension to Regain Compliance With Minimum Bid Price Rule 2
(Date:6/17/2013)... An international team led by scientists at The ... and Albert Einstein College of Medicine of Yeshiva University ... attacks the tuberculosis (TB) bacterium in two different ways. ... one of the major global health crises of our ... said Peter G. Schultz, the Scripps Family Chair Professor ...
(Date:6/17/2013)... In research published in Biochemical and Biophysical Research ... that can detect new, previously unknown viruses. The technique ... when doctors have not identified a particular virus as ... In the new approach, scientists use blood serum as ... Taking advantage of the complete deciphering of the human ...
(Date:6/17/2013)... early onset of puberty in girls, a new clinical ... Endocrine Society,s 95th Annual Meeting in San Francisco. , ... 10 and 14. Boys undergo these changes later, usually ... is diagnosed in girls when sexual development begins before ... when these changes occur before age 9. , Recently, ...
Breaking Biology News(10 mins):New compound excels at killing persistent and drug-resistant tuberculosis 2New compound excels at killing persistent and drug-resistant tuberculosis 3New compound excels at killing persistent and drug-resistant tuberculosis 4Saint Louis University researchers discover a way to detect new viruses 2Saint Louis University researchers discover a way to detect new viruses 3Vitamin D supplementation may delay precocious puberty in girls 2
... Biotechnology: Economics and Policy, edited by Richard ... has won the Quality of Communication Award from ... recognizes publications that demonstrate superior communication of concepts ... Agricultural Biotechnology: Economics and Policy assembles 33 ...
... barcoding experts from 46 nations will converge in ... agencies and others beginning to realize potential applications ... protection and food safety to disease prevention and ... scientific field could, among many other things, help ...
... named as the 2007 winner of the ALPSP/Charlesworth Award ... recognises a significantly innovative approach to any aspect of ... this years award was RSC Project Prospect from the ... of semantics into chemical science publishing. RSC Project Prospect ...
Cached Biology News:Amid spiralling government interest, world's top 350 DNA barcode scientists meet in Taipei 2Amid spiralling government interest, world's top 350 DNA barcode scientists meet in Taipei 3Amid spiralling government interest, world's top 350 DNA barcode scientists meet in Taipei 4Amid spiralling government interest, world's top 350 DNA barcode scientists meet in Taipei 5Amid spiralling government interest, world's top 350 DNA barcode scientists meet in Taipei 6Amid spiralling government interest, world's top 350 DNA barcode scientists meet in Taipei 7Amid spiralling government interest, world's top 350 DNA barcode scientists meet in Taipei 8RSC Project Prospect scoops prestigious award 2
... TempliPhi 100 Amplification Kit, 100 reactions. ... sequencing in 4-6 h.Generate microgram quantities ... of starting material.Use amplified DNA directly ... from bacterial or M13 liquid cultures, ...
... Amplification Kit, 500 reactions. Prepare circular ... 4-6 h.Generate microgram quantities of template ... material.Use amplified DNA directly for cycle ... or M13 liquid cultures, colonies, plaques, ...
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
Mixing speed from 750-3200RPM, small vortexing orbit of1.0mm...
Biology Products: